Tissue Sensitivity Analysis to Assess Drug Response for Precision Medicine

Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster

The approval label of many drugs specifically states use in cancer of a certain tissue type, for instance, breast or lung. In any approach to precision medicine, cancer lineage should therefore be taken into account. Oncolines® includes such tissue type analysis, indicating whether anti-cancer drugs or drug candidates show preferential activity in a certain cancer tissue type. Annotation of disease indication conforms to the Cellosaurus database (Bairoch, 2018). The associated tissue types are hierarchically organized according to the Oncotree classification.

As an example, Oncolines® tissue-type analysis has revealed that the CDK4/6 inhibitor ribociclib (Kisqali®) potently inhibits proliferation of cell lines of neuroblastoma origin. This finding supports ongoing clinical studies (Geoerger et al., 2017).

Flat image preview of online activity plot
Tissue-based boxplot of the Oncolines® profile of CDK4/6 inhibitor ribociclib. Ribociclib is under investigation for neuroblastoma in clinical trials.


Bairoch (2018) The Cellosaurus, a cell line knowledge resource. Journal of Biomolecular Techniques, 29 (2):25-38.

Memorial Sloan Kettering Cancer Center

Geoerger et al. (2017) A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 23 (10):2433-2441.